Uncategorized

 Bloomberg reported in June that Zimvie was considering a sale after receiving takeover approaches. 

Early customer feedback on the new robot suggests features such as improved ergonomics and vision technology are helping drive adoption, executives said.

The cybersecurity firm released what was meant to be a routine software update, but now health systems, including CommonSpirit Health and Cleveland Clinic, are locked out of Windows systems.

While the number of deals reached its lowest levels since 2014, the average deal size for the first half of 2024 was 40% higher than the year prior. 

In a bid to take advantage of Humira’s slow loss of market share, Boehringer Ingelheim is offering its biosimilar at a 92% discount exclusively to patients who buy the product on GoodRx.

While its investigational regimen fell short of the primary efficacy endpoint, AVEO dug into data from its control group and touted a “clinically meaningful” improvement in progression-free survival in patients receiving Fotivda monotherapy.

After a long and challenging journey for its stem cell therapy NurOwn, BrainStorm Cell Therapeutics has aligned with the FDA on the parameters of a Phase IIIb ALS trial that is expected to begin by the end of 2024.

GRO Biosciences will use the Series B funds to launch a Phase I trial for ProGly-Uricase, its investigational therapy for gout.

Drones inspeccionando desde el aire tierras de cultivo para detectar automáticamente la presencia en ellas de malas hierbas u otras amenazas. Puede parecer una escena de ciencia-ficción, pero ya está ocurriendo de verdad, aunque por ahora solo en algunos campos agrícolas …

Los virus de ARN, que tienen el ácido ribonucleico o ARN como material genético en lugar de ADN o ácido desoxirribonucleico, tienen unas de las tasas de mutación más altas de la naturaleza. Esto les permite burlar al sistema inmune para seguir contagiando, y hace m …